# CORRECTION Open Access

# Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy

Anna M. De Kort<sup>1</sup>, H. Bea Kuiperij<sup>1</sup>, Daniel Alcolea<sup>2,3</sup>, Iris Kersten<sup>1</sup>, Alexandra A. M. Versleijen<sup>4</sup>, Steven M. Greenberg<sup>5</sup>, Erik Stoops<sup>6</sup>, Floris H. B. M. Schreuder<sup>1</sup>, Catharina J. M. Klijn<sup>1</sup>, Alberto Lleó<sup>2,3</sup>, Jurgen A. H. R. Claassen<sup>7</sup> and Marcel M. Verbeek<sup>1,4\*</sup>

# Correction to: Alz Res Therapy 13, 160 (2021) https://doi.org/10.1186/s13195-021-00899-0

Following the publication of the original article [1] the authors noticed that the published Fig. 2 is incorrect. The authors uploaded the incorrect figure during the proofing process. The original article [1] has been updated. The correct Fig. 2 is depicted below.

## **Author details**

<sup>1</sup>Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, P.O. Box 9101, 6500, HB, Nijmegen, The Netherlands. <sup>2</sup>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. <sup>3</sup>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain. <sup>4</sup>Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>5</sup>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. <sup>6</sup>ADx NeuroSciences, Ghent, Belgium. <sup>7</sup>Department of Geriatrics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Centre, Nijmegen, The Netherlands.

Published online: 16 November 2021

### Reference

 De Kort AM, Kuiperij HB, Alcolea D, et al. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. Alz Res Therapy. 2021;13:160. https://doi.org/10.1186/s13195-021-00899-0.

The original article can be found online at https://doi.org/10.1186/s13195-021-00899-0.


Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/loublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

<sup>\*</sup>Correspondence: marcel.verbeek@radboudumc.nl

<sup>&</sup>lt;sup>4</sup> Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands



**Fig. 2** A ROC analysis showed moderately high accuracy levels for discrimination of aMCI from control in the Nijmegen aMCI patients and controls (gray line) and the Barcelona aMCI patients and controls (black line). **B** ROC analysis showed consistently high accuracy levels for discrimination of AD from control in the Nijmegen AD patients and controls (gray line) and the Barcelona AD patients and controls (black line). Abbreviations: AD, Alzheimer's disease; AUC area under the curve. The Barcelona cohort serves as a validation cohort